Human Insulin market research provides a new perspective into the components and workings on global as well as regional levels. The report serving as an invaluable source of guidance for readers covers an analysis overview of the industry chain of the global market and discusses key elements associated with it, the report focuses on the global status, future forecast, growth opportunity, key market, and key players.
The global Human Insulin market size was estimated at USD 25.96 billion in 2023 and is projected to reach USD 33.38 billion in 2030 at a CAGR of 3.2% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/human-insulin-market
Human Insulin or Insulin is a hormone produced in the human pancreas that regulates the amount of glucose (sugar) in the bloodstream and the metabolism of fats, proteins and carbohydrates in the human body. Insulin is available in different strengths; the most common is U-100, which is used as a dietary and exercise supplement to improve glucose balance in children and adults.
The growth of the global market is attributed to key factors such as increasing demand for human insulin analogues and affordable reimbursements. Technological innovations in human insulin delivery devices are also boosting the market. For example, in August 2020, the US FDA approved the MiniMed 770G, an innovative diabetes management device. This device automatically monitors glucose levels and delivers the correct basal insulin doses to pediatric patients with type 1 diabetes with minimal client (caregiver) input.
Delvens Industry Expert's Standpoint
The global Human Insulin market is driven by advances in technology, increasing RD funding, increasing government support and prevalence of diabetes. In addition, RD's role in the insulin market is increasing as researchers around the world strive to develop a better insulin molecule for diabetics that increases efficacy and reduces side effects. In addition, the market is expected to grow in the absence of drug cap rules, which will result in several major pharmaceutical companies raising the prices of generic drugs, including insulin. Global market players can also capitalize on the opportunities in the premixed insulin segment due to its ease of use and portability, as well as premixed insulin delivery devices.
Competitive Landscape
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc.
- Biocon Ltd
- Wockhardt
- Boehringer Ingelheim International GmbH
- Julphar
- United Laboratories International Holdings Limited
- Tonghua Dongbao Pharmaceutical Co. Ltd.
- Exir
- Sedico
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Oramed
- Adocia
- Merck co. Inc
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/human-insulin-market
Key Findings
- By product, the human insulin market is divided into two main segments: drugs and dosing devices. The human insulin drug segment is expected to account for the largest share of the global market by product in 2022.
- The application segment is further bifurcated into type-1 and type-2 diabetes. The largest segment by application is type 1 diabetes mellitus, due to the high insulin dependency of these patients. It is a more severe condition than type 2 diabetes.
- By product type, the human insulin device market is divided into three segments: pens, pen needles and syringes. The pen segment is expected to account for the largest market share in 2022; it will be the fastest growing segment in the next five years.
- The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America due to the dominance of branded products and the increasing prevalence of disease in the region.
Recent Developments
- November 2022: The U.S. Food and Drug Administration approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type-1 diabetics and pediatric patients 8 years of age and older who were stage 2 type-1 diabetics.
- May 2022: The FDA approved Lilly’s new medication Mounjaro (also known as tirzepatide) for type-2 diabetes management in addition to diet and exercise. This first-in-class medication showed improvement in glucose levels and also dramatically improved weight in clinical trials.
Access Full Report: https://www.delvens.com/report/human-insulin-market
In addition to the market data for the Human Insulin Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
Reasons to Acquire
- Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
- Gain authentic and granular data access for the Human Insulin Market to understand the trends and the factors involved in changing market situations.
- Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
- In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Browse More Reports from Delvens:
Assisted Living (AL) market size was estimated at USD 180.70 billion in 2023 and is projected to reach USD 305.70 billion in 2030 at a CAGR of 7.8% during the forecast period 2023-2030.
Congenital Heart Disease (CHD) market size was estimated at USD 4.47 billion in 2023 and is projected to reach USD 8.11 billion in 2030 at a CAGR of 8.87% during the forecast period 2023-2030.
Periodontal Disease Treatment market size was estimated at USD 799.17 million in 2023 and is projected to reach USD 1438.54 million in 2030 at a CAGR of 8.76% during the forecast period 2023-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT Telecom, Chemicals Materials, Semiconductor Electronics, Energy, Pharmaceutical, Consumer Goods Services, Food Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
